Opponents to Takeda’s $62B buyout of Shire gain support but need much more

Takeda Grange Castle Ireland
Takeda, which has this manufacturing site at Grange Castle, Ireland, said that it expects to get $1.4 billion in cost savings over the next three years after its $62B buyout of Shire. (Takeda)

Takeda shareholders who oppose the company’s $62 billion buyout of Shire are gaining support for their effort to block the deal, which they say will shrink the value of Takeda shares.

What started out as a dozen dissenters has grown to 130 in opposition. It includes former employees and members of the founding Takeda family, which hold 10% of the company’s shares, Reuters reported, citing unnamed sources.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

That is still a long way from the 33% of shareholders that is needed to derail the deal by Japan’s largest drugmaker. The dissenters are hoping to gain support from retail customers in Japan, which hold about 25% of shares, a source tells Reuters. That is an unusually large percentage for any large public company. They also are soliciting foreign institutional investors, the source said.

The opposition group, which has pointed out that Takeda would have to take on significant debt to pay for the deal, wants the company to vote on the Shire buyout at the annual shareholder meeting. But the Takeda board intends to hold a separate meeting to decide the outcome. It has said the acquisition was made “after repetitive and careful discussion” by board members.

RELATED: Takeda to vault into Big Pharma with $62B Shire buyout—and megamerger cuts are on the way

The Japanese pharma company has been selling the deal to shareholders as a way to create a global leader in gastroenterology and neuroscience, while simultaneously boosting the company’s presence in vaccines, rare diseases and oncology. It has said it expects to extract $1.4 billion in cost savings over the next three years by slashing the combined workforce by up to 7%, what amounts to 3,600 jobs. The cuts are expected to hit SG&A, R&D and manufacturing.

The opposing shareholders noted that Takeda intends to finance about 55% of the Shire takeover with newly issued shares. That “might significantly dilute the earnings per share, which is a dividend resource, and there is a danger of causing a great disadvantage to existing shareholders including institutional investors,” their proposal said. The shareholders also expressed concerns about the deal in light of Takeda’s “current financial situation.”

Suggested Articles

One year after its landmark Reduce-It CV outcomes trial, Amarin has new data showing its Vascepa may help halt the progress of arterial plaque.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.